HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European...

Related Keywords

San Diego ,California ,United States ,David Rosen ,Schottlandt Claudia Styslinger ,Helen Torley ,Covis Pharma ,Eli Lilly ,Bristol Myers Squibb ,Linkedin ,Janssen Biotech Inc ,Teva Pharmaceutical ,Twitter ,Company Anticipates No Impact ,Opposition Division ,Nasdaq ,Halozyme Therapeutics Inc ,Exchange Commission ,Pfizer ,Opposition Division Of The European Patent Office ,Idorsia Pharmaceuticals ,Corporate Communications ,Prnewswire Halozyme Therapeutics Inc ,European Royalty Revenues ,Royalty Revenue ,European Patent Office ,Janssen Biotech ,European Patent ,Horizon Therapeutics ,Viiv Healthcare ,Annual Report ,Investor Relations ,Halozyme Therapeutics ,Nc ,